The clinical importance of NO/sGC/cGMP signalling in cardiovascular and cardio-renal diseases including HF is very obvious; however, a better understanding of the underlying mechanisms is necessary for the optimal HF treatment and prevention and selection of patients profiting best from sGC stimulator therapies (Numata and Takimoto 2022). Here, SGCB is linked to hydrops fetalis.